Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280674 | 1.00 | TTR (0.58) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL69618 | 0.93 | TTR (0.66) | TTRAPPPTPN1CA12CA1 | |
| 3-Formylbenzoic Acid SCHEMBL4423592 | 0.88 | UNG (0.66) | TTRAPPPTPN1CA12CA1 | |
| 3-Formylbenzoic Acid SCHEMBL4423601 | 0.88 | UNG (0.66) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL4423599 | 0.87 | P4HB (0.53) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL2631340 | 0.84 | CA12 (0.66) | TTRAPPPTPN1CA12CA1 | |
| E-Methyl Cinnamate SCHEMBL5487323 | 0.84 | KMT2A (0.68) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL30676338 | 0.84 | CA12 (0.66) | TTRAPPPTPN1CA12CA1 | |
| E-Methyl Cinnamate SCHEMBL5487325 | 0.84 | KMT2A (0.68) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL3065424 | 0.84 | CA12 (0.66) | TTRAPPPTPN1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989478-B2 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7381825-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-7375228-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7169801-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060211680-A1 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-09-21 | — | — | US | disclosed |
| EP-1671948-A1 | CINNAMOYL COMPOUND AND USE OF THE SAME | Sumitomo Chemical Company, Limited (JP) | 2006-06-21 | — | — | EP | disclosed |
| EP-1608628-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050137232-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | disclosed |
| US-20040266769-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040254220-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004082638-A2 | HISTONE DEACETYLASE INHIBITORS | SYRRX, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-5756527-A | ANTICARCINOGENIC AGENTS | ONTOGEN CORPORATION (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0812830-A1 | Modulators of multi-drug resistances | ONTOGEN CORPORATION (US) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137232-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC10 | TTR 4843/4885APP 4496/4885PTPN1 4273/4885 |
| US-20060211680-A1 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | COL2A1, COL1A1, COL14A1 | TTR 3910/4885APP 3864/4885PTPN1 3840/4885 |
| US-20040266769-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC10 | TTR 4843/4885APP 4496/4885PTPN1 4273/4885 |
| US-20040254220-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC10 | TTR 4843/4885APP 4496/4885PTPN1 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.